Xenon Pharmaceuticals (XENE) Competitors $30.46 -0.97 (-3.09%) Closing price 04:00 PM EasternExtended Trading$30.46 0.00 (0.00%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. VTRS, MRNA, QGEN, ASND, ROIV, RVMD, BBIO, BPMC, ELAN, and LEGNShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines BridgeBio Pharma Blueprint Medicines Elanco Animal Health Legend Biotech Viatris (NASDAQ:VTRS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Do insiders and institutionals have more ownership in VTRS or XENE? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate VTRS or XENE? Viatris currently has a consensus target price of $10.50, suggesting a potential upside of 21.32%. Xenon Pharmaceuticals has a consensus target price of $54.82, suggesting a potential upside of 76.59%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in VTRS or XENE? Xenon Pharmaceuticals received 409 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 69.79% of users gave Xenon Pharmaceuticals an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformViatrisOutperform Votes2334.85% Underperform Votes4365.15% Xenon PharmaceuticalsOutperform Votes43269.79% Underperform Votes18730.21% Which has more risk & volatility, VTRS or XENE? Viatris has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Which has preferable earnings and valuation, VTRS or XENE? Viatris has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.33B0.71$54.70M-$3.17-2.73Xenon Pharmaceuticals$7.50M317.60-$182.39M-$3.23-9.61 Does the media favor VTRS or XENE? In the previous week, Xenon Pharmaceuticals had 15 more articles in the media than Viatris. MarketBeat recorded 48 mentions for Xenon Pharmaceuticals and 33 mentions for Viatris. Xenon Pharmaceuticals' average media sentiment score of 0.49 beat Viatris' score of 0.01 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 2 Positive mention(s) 24 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Xenon Pharmaceuticals 14 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Is VTRS or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-5.87% 16.46% 7.09% Xenon Pharmaceuticals N/A -24.69%-23.68% SummaryXenon Pharmaceuticals beats Viatris on 13 of the 18 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.39B$6.58B$5.41B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-11.029.2126.7719.96Price / Sales317.60257.57395.44121.37Price / CashN/A65.8538.2534.62Price / Book2.196.576.874.60Net Income-$182.39M$144.25M$3.23B$248.27M7 Day Performance4.38%5.13%5.32%2.28%1 Month Performance-10.54%9.67%13.56%16.43%1 Year Performance-20.36%-0.88%17.86%8.15% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals3.2254 of 5 stars$30.46-3.1%$54.82+80.0%-22.2%$2.34B$7.50M-10.80210Analyst DowngradeVTRSViatris2.0723 of 5 stars$8.96+2.2%$10.50+17.2%-19.8%$10.63B$14.33B-12.1137,000Trending NewsGap UpMRNAModerna4.5365 of 5 stars$25.70+6.0%$53.95+109.9%-80.2%$9.94B$3.14B-2.773,900Trending NewsQGENQiagen3.9935 of 5 stars$42.92+2.5%$48.42+12.8%-3.4%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.508 of 5 stars$154.43+2.1%$216.07+39.9%+33.5%$9.42B$368.70M-21.75640Positive NewsROIVRoivant Sciences1.9729 of 5 stars$10.99+3.3%$17.50+59.2%-2.9%$7.84B$122.59M-73.26860Positive NewsRVMDRevolution Medicines4.366 of 5 stars$41.88+3.6%$67.17+60.4%+1.1%$7.80B$742,000.00-11.67250Positive NewsBBIOBridgeBio Pharma4.6002 of 5 stars$35.68+4.4%$57.09+60.0%+14.2%$6.77B$127.42M-12.52400Insider TradeBPMCBlueprint Medicines1.7929 of 5 stars$100.31+3.2%$126.56+26.2%-1.2%$6.48B$562.12M-92.88640Positive NewsInsider TradeELANElanco Animal Health3.2195 of 5 stars$12.82+7.2%$15.00+17.0%-23.1%$6.36B$4.43B32.049,800Analyst ForecastGap UpLEGNLegend Biotech3.5319 of 5 stars$32.38+1.9%$78.82+143.4%-33.8%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionGap Up Related Companies and Tools Related Companies Viatris Alternatives Moderna Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts